ABSTRACT OBJECTIVES This study sought to determine the benefits of adding oral anticoagulation therapy in patients with anterior wall ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PCI).
and a P2Y 12 inhibitor reduces stent thrombosis and reinfarction after coronary stenting compared with aspirin alone or aspirin plus warfarin (1) (2) (3) (4) .
In some patients treated with primary PCI, there is need to add oral anticoagulants to prevent thromboembolic events. However, there is mounting evidence that the combination of DAPT and oral anticoagulation (triple therapy) is associated with bleeding The transthoracic echocardiography (TTE) is the most widely used tool to assess for LV thrombus and wall motion abnormalities after anterior STEMI.
Although there is consensus to add oral anticoagulants when LV thrombus is identified, the role of anticoagulants in patients with apical akinesis or dyskinesis without demonstrated LV thrombus remains controversial. Moreover, the safety of this approach in the latter group is poorly documented and represents a major therapeutic dilemma. As randomized trials have yet to be done, we used our database to provide insight into this important management question.
METHODS
PATIENT SELECTION. During the study period, the University of Ottawa Heart Institute provided primary PCI as the dominant reperfusion strategy for STEMI patients presenting in our local health network (10) .
Since the inception of our regional STEMI system, all data pertaining to primary PCI have been entered in the institution's database. In this context, we identi- previous intracranial bleeding; in-hospital bleeding or stroke occurring before baseline TTE; and TTE was of suboptimal quality, not performed, or performed >7 days after the admission. We also excluded patients who died within 72 h of admission or in the setting of ongoing cardiogenic shock or anoxic encephalopathy.
STANDARD THERAPY. All patients received 160 mg chewable aspirin, 600 mg oral clopidogrel, and 60 U/kg intravenous unfractionated heparin to a maximal dose of 4,000 U before catheterization. The PCI procedure was performed according to the standard of practice. After the PCI, aspirin 81 mg/day was prescribed to be continued indefinitely and clopidogrel 75 mg/day for up to 1 year. Patients were monitored in the cardiac intensive care unit and, when deemed stable, were transferred to the ward.
All patients were treated with intravenous heparin after the PCI until TTE was performed. The decision to add warfarin was at the discretion of the treating cardiologist. In patients deemed not to require oral anticoagulants, heparin was discontinued immediately after TTE; however, it was continued as bridging therapy in patients started on warfarin. In these patients, warfarin was prescribed for 3 to 6 months and the international normalized ratio (INR) was adjusted between 2.0 and 3.0 as per prevailing guidelines (11, 12) .
Patients were followed in the clinic at the University of Ottawa Heart Institute, and telephone follow-up was performed when a visit was not possible.
ECHOCARDIOGRAPHY. TTE images were acquired using the following systems: the iE33 Echocardiography System (Philips Healthcare, Andover, Massachusetts), the Sono's 5500 (Philips Healthcare) or the were analyzed with the Mann-Whitney U test. The LV ejection fraction and the apical score were compared between baseline and follow-up TTE studies using a paired t test. A propensity score was generated using the baseline variables, and the impact of warfarin therapy on NACE at 180 days was assessed on the basis of a propensity score analysis using inverse probability weighting in a logistic regression model. In addition, a multivariable analysis using a logistic regression model was performed to determine the independent effect of adding warfarin therapy on NACE, controlling for differences in baseline variables with p < 0.10 by univariable analysis. A 2-sided p value #0.05 was considered statistically significant. Analyses were conducted using SAS version 9.13 (SAS Institute, Cary, North Carolina). Similarly, in the no warfarin group, the LV ejection fraction increased from 43.6 AE 8.5 to 47.8 AE 11.0 (p < 0.0001), and the apical score decreased from 11.3 AE 1.8 to 9.1 AE 3.9 (p < 0.0001). Apical akinesis or dyskinesis was no longer present in 21% of patients An apical score was generated by summing the scores of the 4 individual apical segments reported on the transthoracic echocardiography: the range for an apical score was 6 to 20.
The figure highlights the extent of overlap between the 2 groups. LV ¼ left ventricular.
Le May et al. Most studies comparing outcomes between triple therapy and DAPT typically included patients with different indications for warfarin therapy, the most frequent being atrial fibrillation. In 1 retrospective study involving 426 patients with atrial fibrillation undergoing coronary stenting, nonanticoagulation with warfarin was an independent predictor of increased mortality (19) . A recent meta-analysis of nonrandomized studies suggested that triple therapy is more efficacious than DAPT in the prevention of major adverse cardiovascular events including allcause mortality (20) . However, in this meta-analysis, warfarin therapy was prescribed mostly for atrial In (24) , and several studies found a link between blood transfusion and excess mortality (24) (25) (26) (27) . Second, we did not report the INR measurements at the time of the events. Current guidelines recommend that the INR be tightly controlled when warfarin therapy is added to DAPT (9) . One study found that INR values were higher in patients on triple therapy who experienced a bleeding complication (8) . However, a recent study concluded that triple therapy compared with DAPT predisposes patients to an increased risk of major bleeding complications regardless of the time spent in the therapeutic anticoagulation range (28) .
CONCLUSIONS
Our results do not support the addition of warfarin therapy after primary PCI in patients with apical akinesis or dyskinesis. Review of the current guidelines may be warranted.
